-
Something wrong with this record ?
Levels of 17β-hydroxysteroid dehydrogenase type 10 in CSF are not a valuable biomarker for multiple sclerosis
Z. Kristofikova, J. Ricny, D. Kaping, J. Klaschka, J. Kotoucova, A. Bartos
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NV16-27611A
MZ0
CEP Register
Digital library NLK
Full text - Article
NLK
PubMed Central
from 2015 to 1 year ago
ProQuest Central
from 2007-06-01 to 2021-01-31
Health & Medicine (ProQuest)
from 2007-06-01 to 2021-01-31
Public Health Database (ProQuest)
from 2007-06-01 to 2021-01-31
PubMed
30520659
DOI
10.2217/bmm-2018-0061
Knihovny.cz E-resources
- MeSH
- 3-Hydroxyacyl CoA Dehydrogenases cerebrospinal fluid MeSH
- Amyloid beta-Peptides cerebrospinal fluid MeSH
- Biomarkers cerebrospinal fluid MeSH
- Adult MeSH
- Humans MeSH
- Peptide Fragments cerebrospinal fluid MeSH
- Multiple Sclerosis cerebrospinal fluid MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
AIM: We aimed to characterize the role of mitochondrial 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) overexpression in multiple sclerosis (MS) and to evaluate its use as a biomarker. Materials & methods: We estimated levels of 17β-HSD10, amyloid β 1-42, cyclophilin D, 17β-HSD10-cyclophilin D complexes or 17β-HSD10-parkin complexes in cerebrospinal fluid (CSF) samples. RESULTS: The increase in 17β-HSD10 levels or in 17β-HSD10-parkin complexes and links to leukocytes were found only in relapsing-remitting MS. The sensitivity of the biomarker was 64%, the specificity equaled 60-63% compared with controls. CONCLUSION: Increased CSF levels of 17β-HSD10 in later stages of MS could be interpreted via its upregulation in demyelinated neuronal axons. CSF levels of 17β-HSD10 are not the valuable biomarker for the early diagnosis or for the progression of MS.
Institute of Computer Science Academy of Sciences 182 07 Prague Czech Republic
National Institute of Mental Health 250 67 Klecany Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21029263
- 003
- CZ-PrNML
- 005
- 20211203142145.0
- 007
- ta
- 008
- 211203s2018 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2217/bmm-2018-0061 $2 doi
- 035 __
- $a (PubMed)30520659
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kristofikova, Zdenka $u National Institute of Mental Health, 250 67 Klecany, Czech Republic
- 245 10
- $a Levels of 17β-hydroxysteroid dehydrogenase type 10 in CSF are not a valuable biomarker for multiple sclerosis / $c Z. Kristofikova, J. Ricny, D. Kaping, J. Klaschka, J. Kotoucova, A. Bartos
- 520 9_
- $a AIM: We aimed to characterize the role of mitochondrial 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) overexpression in multiple sclerosis (MS) and to evaluate its use as a biomarker. Materials & methods: We estimated levels of 17β-HSD10, amyloid β 1-42, cyclophilin D, 17β-HSD10-cyclophilin D complexes or 17β-HSD10-parkin complexes in cerebrospinal fluid (CSF) samples. RESULTS: The increase in 17β-HSD10 levels or in 17β-HSD10-parkin complexes and links to leukocytes were found only in relapsing-remitting MS. The sensitivity of the biomarker was 64%, the specificity equaled 60-63% compared with controls. CONCLUSION: Increased CSF levels of 17β-HSD10 in later stages of MS could be interpreted via its upregulation in demyelinated neuronal axons. CSF levels of 17β-HSD10 are not the valuable biomarker for the early diagnosis or for the progression of MS.
- 650 _2
- $a 3-hydroxyacyl-CoA-dehydrogenasy $x mozkomíšní mok $7 D015094
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a amyloidní beta-protein $x mozkomíšní mok $7 D016229
- 650 _2
- $a biologické markery $x mozkomíšní mok $7 D015415
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a roztroušená skleróza $x mozkomíšní mok $7 D009103
- 650 _2
- $a peptidové fragmenty $x mozkomíšní mok $7 D010446
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ricny, Jan $u National Institute of Mental Health, 250 67 Klecany, Czech Republic
- 700 1_
- $a Kaping, Daniel $u National Institute of Mental Health, 250 67 Klecany, Czech Republic
- 700 1_
- $a Klaschka, Jan $u Institute of Computer Science, Academy of Sciences, 182 07 Prague, Czech Republic
- 700 1_
- $a Kotoucova, Jolana $u National Institute of Mental Health, 250 67 Klecany, Czech Republic
- 700 1_
- $a Bartos, Ales $u National Institute of Mental Health, 250 67 Klecany, Czech Republic $u Department of Neurology, Third Faculty of Medicine, University Hospital Kralovske Vinohrady, Charles University, 100 34 Prague, Czech Republic
- 773 0_
- $w MED00172897 $t Biomarkers in medicine $x 1752-0371 $g Roč. 12, č. 12 (2018), s. 1331-1340
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30520659 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211203 $b ABA008
- 991 __
- $a 20211203142140 $b ABA008
- 999 __
- $a ok $b bmc $g 1730260 $s 1149816
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 12 $c 12 $d 1331-1340 $e 20181206 $i 1752-0371 $m Biomarkers in medicine $n Biomark Med $x MED00172897
- GRA __
- $a NV16-27611A $p MZ0
- LZP __
- $a 2021-granty
